Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 772-781

  Weiss, Brianne ^a   Alt, Andrew ^a   Ogden, Ann Marie ^a   Gates, Mary ^a   Dieckman, Donna K ^a   Clemens Smith, Amy ^a   Ho, Ken H ^b   Jarvie, Keith ^b   Rizkalla, Geihan ^b   Wright, Rebecca A ^a   Calligaro, David O ^a   Schoepp, Darryle ^a   Mattiuz, Edward L ^a   Stratford, Robert E ^a   Johnson, Bryan ^a   Salhoff, Craig ^a   Katofiasc, Mary ^a   Phebus, Lee A ^a   Schenck, Kathryn ^a   Cohen, Marlene ^a   Filla, Sandra A ^a   Ornstein, Paul L ^a   Johnson, Kirk W ^a   Bleakman, David ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 (4 CARBOXYBENZYL) 1,2,3,4,4A,5,6,7,8,8A DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; [(2 CARBOXY 4,4 DIFLUORO 1 PYRROLIDINYL)METHYL]DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DECAHYDROISOQUINOLINE; ESTER; GLUCOKINASE; KAINIC ACID RECEPTOR ANTAGONIST; PLASMA PROTEIN; PRODRUG; UNCLASSIFIED DRUG;

AFFINITY LABELING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CAUDATE NUCLEUS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; GENE EXPRESSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MIGRAINE; MOTOR ACTIVITY; MUSCLE CONTRACTILITY; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SAPHENOUS VEIN; SPINAL GANGLION; TRIGEMINUS GANGLION; VASOCONSTRICTION;

ANIMALS; BENZODIAZEPINES; BINDING, COMPETITIVE; BLOOD PROTEINS; CALCIUM; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; ISOQUINOLINES; LIGANDS; MALE; MIGRAINE DISORDERS; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NEURONS; PHENCYCLIDINE; PROTO-ONCOGENE PROTEINS C-FOS; RABBITS; RATS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; SAPHENOUS VEIN; TRANSFECTION;

EID: 33746027410     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.101428     Document Type: Article

References (36)

1. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, and Bleakman D (2004) Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46:739-806.
2. Alt A, Weiss B, Ogden AM, Li X, Gleason S, Calligaro DO, Bleakman D, and Witkin JM (2006) In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology 185:240-247.
3. Bleakman D, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, and Kamboj RK (1996) Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl] decahydroisoquinoline-3 carboxylic acid. Mol Pharmacol 49:581-585.
4. Bleakman D, Ogden AM, Ornstein PL, and Hoo K (1999) Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur J Pharmacol 378:331-337.
5. Bortolotto ZA, Clarke VRJ, Delany CM, Parry MC, Smolders I, Vignes M, Ho KH, Miu P, Brinton BT, Fantaske R, et al. (1999) Kainate receptors are involved in synaptic plasticity. Nature (Lond) 402:297-301.
6. Buzzi MG and Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202-206.
7. Christensen JK, Paternain AV, Selak S, Ahring PK, and Lerma J (2004a) A mosaic of functional kainate receptors in hippocampal interneurons. J Neurosci 24:8986-8993.
8. K5 receptors. J Pharmacol Exp Ther 309:1003-1010.
9. Clarke VRJ, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, et al. (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature (Lond) 389:599-603.
10. Cohen ML, Johnson KW, Schenck KW, and Phebus LA (1997) Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 17:631-638.
11. Collingridge GL and Lester RA (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 4:143-210.
12. Filla SA, Winter MA, Johnson KW, Bleakman D, Bell MG, Bleisch TJ, Castaño AM, Clemens-Smith A, del Prado M, Dieckman DK, et al. (2002) Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3- carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two models of acute migraine. J Med Chem 45:4383-4386.
13. Frolund B, Greenwood JR, Holm MM, Egebjerg J, Madsen U, Nielsen B, Brauner-Osborne H, Stensbøl TB, and Krogsgaard-Larsen P (2005) Tetrazolyl isoxazole amino acids as ionotropic glutamate receptor antagonists: synthesis, modelling and molecular pharmacology. Bioorg Med Chem 13:5391-5398.
14. 1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358:1230-1234.
15. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
16. Hoo KH, Nutt SL, Fletcher EJ, Elliott CE, Korczak B, Deverill RM, Rampersad V, Fantaske RP, and Kamboj RK (1994) Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit. Receptors Channels 2:327-337.
17. Huettner JE (1990) Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by con A. Neuron 5:255-266.
18. 3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGLU) receptors: characterization of binding to membranes of mGLU receptor subtype expressing cells. Neuropharmacology 38:1519-1529.
19. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 8:2237-2240.
20. Korczak B, Nutt SL, Fletcher EJ, Hoo KH, Elliott CE, Rampersad V, McWhinnie EA, and Kamboj RK (1995) cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. Receptors Channels 3:41-49.
21. Maassen VanDenBrink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauwerse HG, Saxena PR, Ferrari MD, and Frants RR (1998) Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 77:415-420.
22. Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, and Moskowitz MA (1999) Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 127:623-630.
23. Møller EH, Egebjerg J, Brehm L, Stensbøl TB, Johansen TN, Madsen U, and Krogsgaard-Larsen P (1999) Resolution, absolute stereochemistry and enantiopharmacology of the GluR1-4 and GluR5 antagonist 2-amino-3-[5-tert- butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid. Chirality 11:752-759.
24. More JC, Nistico R, Dolman NP, Clarke VR, Alt AJ, Ogden AM, Buelens FP, Troop HM, Kelland EE, Pilato F, et al. (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47:46-64.
25. O'Neill MJ, Bond A, Ornstein PL, Ward MA, Hicks CA, Hoo K, Bleakman D, and Lodge D (1998) Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 37:1211-1222.
26. Ornstein PL, Schoepp DD, Arnold MB, Augenstein NK, Lodge D, Millar JD, Chambers J, Campbell J, Paschal JW, Zimmerman DM, et al. (1992) 6-Substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. J Med Chem 35:3547-3560.
27. Partin KM, Patneau DK, Winters CA, Mayer ML, and Buonanno A (1993) Selective modulation of desensitization at AMPA and kainate receptors by cyclothiazide and concanavalin A. Neuron 11:1069-1082.
28. Paternain AV, Morales M, and Lerma J (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14:185-189.
29. Sahara Y, Noro N, Iida Y, Soma K, and Nakamura Y (1997) Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 17:6611-6620.
30. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, et al. (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24:596-602.
31. Savidge JR, Bleakman D, and Bristow DR (1997) Identification of kainate receptor-mediated intracellular calcium increases in cultured rat cerebellar granule cells. J Neurochem 69:1763-1766.
32. Schoepp DD, Ornstein PL, Salhoff CR, and Leander JD (1991) Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist. J Neural Transm Gen Sect 85:131-143.
33. Small B, Thomas J, Kemp M, Hoo K, Ballyk B, Deverill M, Ogden AM, Rubio A, Pedregal C, and Bleakman D (1998) LY339434, a GluR5 kainate receptor agonist. Neuropharmacology 37:1261-1267.
34. K5-containing receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 5:796-804.
35. Vignes M, Bleakman D, Lodge D, and Collingridge GL (1997) The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus. Neuropharmacology 36:1477-1481.
36. Wilding TJ and Huettner JE (1996) Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol Pharmacol 49:540-546.